top of page
Search

Validating CNS Therapeutics

Updated: 4 days ago

The Critical Role of Human Tissue Analysis in Recent Drug Development Studies

The development of therapeutics for Central Nervous System (CNS) disorders is fraught with translational challenges. Animal models often fail to capture the full complexity of human neurodegenerative disease, contributing to a high rate of clinical trial failure. Consequently, validating novel diagnostics and therapeutics directly in human CNS tissue has become a critical step for de-risking clinical development. This approach provides essential data on target engagement, specificity, and mechanism of action in the only truly relevant biological context.


A series of recent publications highlight how advanced in vitro and ex vivo techniques using post-mortem human brain tissue can answer fundamental questions in CNS drug development. These studies, focusing on diverse modalities from PET radioligands to therapeutic antibodies, underscore the value of quantitative, pathology-driven analysis.




Characterizing Novel PET Ligands for Synucleinopathies and Tauopathies


The development of selective PET radioligands is crucial for early diagnosis and therapeutic monitoring. A primary challenge is ensuring that a ligand binds with high affinity to its intended pathological protein target (e.g., α-synuclein, tau) without significant off-target binding to other protein aggregates (e.g., amyloid-β) that often co-exist in the diseased brain.


In recent studies characterizing two novel PET ligands, KAC-50.1 and [3H]GMC-058, a key component was the extensive in vitro validation using quantitative autoradiography on a comprehensive panel of human brain tissues. For KAC-50.1, its binding profile was assessed on tissues with high α-synuclein pathology as well as cases of Alzheimer’s Disease (AD), Progressive Supranuclear Palsy (PSP), and Corticobasal Degeneration (CBD) to map its selectivity. A similar strategy was employed for [3H]GMC-058, using tissue microarrays from Parkinson’s Disease (PD), Multiple System Atrophy (MSA), AD, PSP, and CBD cases, alongside saturation binding assays on brain homogenates to determine binding affinities (KD).




This rigorous profiling demonstrated that while KAC-50.1 bound to α-synuclein, it also showed significant binding to amyloid-β and tau, indicating a lack of selectivity that halted its further development. Conversely, [3H]GMC-058 displayed low affinity for α-synuclein in PD and MSA but higher affinity for pathologies in PSP, CBD, and AD, suggesting its potential as a tracer for 4R tauopathies.

Insight: Quantitative autoradiography across a broad panel of pathologically diverse neurodegenerative tissues is essential for distinguishing on-target affinity from off-target binding, providing definitive go/no-go data on tracer selectivity.


Immunohistochemical staining of human brain sections from various patients with different alpha-synucleopathies.

Confirming Target Engagement for the α-Synuclein Antibody Exidavnemab


For a therapeutic antibody, demonstrating selective engagement with the pathogenic conformation of a target protein within the complex environment of the human brain is a prerequisite for success. In a 2025 study, BioArctic’s antibody, Exidavnemab, was evaluated for its ability to bind aggregated α-synuclein.



Crucial ex vivo evidence for target engagement was provided through detailed immunohistochemistry (IHC) on post-mortem brain tissues from patients with PD, Dementia with Lewy Bodies (DLB), and MSA. The analysis confirmed that Exidavnemab robustly bound to pathological α-synuclein aggregates (e.g., Lewy bodies and Lewy neurites). To further probe this selectivity, immunoprecipitation experiments were performed on Triton-soluble brain extracts, which showed that the antibody could effectively capture and remove α-synuclein aggregates. Together, these results confirmed a high affinity for pathological, aggregated protein conformations with low affinity for the native monomeric form.

Insight: Combining IHC with biochemical methods like immunoprecipitation on diseased human tissue is vital to confirm that a therapeutic antibody selectively engages the intended pathogenic conformation of its target, moving beyond simple co-localization.


Correlating In Vivo PET Signal with Ground-Truth Neuropathology

Corticobasal Syndrome (CBS) is a clinical diagnosis with heterogeneous underlying pathologies, including 4-repeat (4R) tauopathy or Alzheimer's disease. This presents a challenge for interpreting in vivo imaging data, which must be validated against the "ground truth" of the actual tissue pathology.



A 2023 study assessing the tau PET ligand [11C]PBB3 in CBS patients stratified by amyloid-β status required such validation. To anchor the in vivo imaging to the underlying pathology, a comprehensive post-mortem neuropathological workup was performed on the brain of a CBS patient who had undergone PET imaging. Detailed IHC staining for hyperphosphorylated tau and amyloid-β confirmed the diagnosis of Corticobasal Degeneration (CBD). Crucially, the histopathology showed that the tracer's autofluorescence co-localized with only a subset of the tau-positive inclusions, providing a vital insight into the ligand’s binding characteristics and its partial sensitivity for 4R tauopathy.

Insight: Direct post-mortem neuropathological correlation is the definitive method for validating an in vivo imaging signal, providing the ground truth required to interpret PET data from clinically and pathologically heterogeneous patient populations.

A Convergent Approach to De-Risking

Recent breakthroughs in CNS therapeutic developments demonstrate a common theme: the power of applying advanced tissue analysis techniques directly to well-characterized human biospecimens to answer fundamental scientific questions. Whether it's defining the selectivity of a small molecule, confirming the target of a biologic, or validating a clinical imaging signal, a human tissue-first approach provides a layer of data that is otherwise unobtainable. This convergent methodology, which integrates quantitative autoradiography, multi-label IHC, and direct pathological correlation, is becoming an indispensable part of the modern CNS drug development pathway, offering a more robust, evidence-based foundation for making critical go/no-go decisions.


Read the Full Stories and more on our publications page.



Post: Blog2_Post
bottom of page